Navigation Links
World's First Cardiac Adult Stem Cell Patient Receives Infusion
Date:7/24/2009

Trial taking place in Louisville, KY

LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- Michael (Mike) Jones has become the world's first recipient of adult cardiac stem cells to treat congestive heart failure. Jones' infusion on July 17 marks the world's first phase-one FDA-approved clinical trial using adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital.

During the infusion procedure, Jones was directly injected with his own cardiac stem cells into heart scar tissue using a minimally-invasive cardiac catheterization procedure, which reaches the heart through an artery in the patient's leg. The 66-year-old, self-employed man continues to recover following the outpatient procedure.

Mark Slaughter, M.D., Chief of the Division of Cardiothoracic Surgery at UofL and Director of the Heart Transplant and Mechanical Assist Device Program at Jewish Hospital, performed coronary artery bypass surgery on Jones on March 23. Jones suffered from congestive heart failure due to multiple blocked arteries that had resulted in permanent scarring of his heart muscle. During the procedure, Jones' cardiac stem cells were retrieved from a portion of his own atrium, the upper chamber of the heart. The tissue was then sent to Piero Anversa, of Harvard University and Brigham & Women's Hospital in Boston, for processing and to grow cardiac stem cells from Jones' tissue.

Jones' infusion procedure was performed at Jewish Hospital by Sohail Ikram, M.D., UofL Professor of Medicine and Director and Chief of Invasive and Interventional Cardiology at Jewish Hospital.

Study leader Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for Molecular Cardiology said, "We continue to enroll patients in this first-of-its-kind clinical trial. We hope to help the heart regenerate its own tissue and improve heart function." Bolli is collaborating with a number of leaders in the field of cardiovascular and stem cell medicine for this clinical trial.

The team will continue to evaluate Jones, as well as other patients who have enrolled in the clinical trial, for heart function and blood flow. In addition, the heart's overall size and the size of the scar tissue will be measured.

Since this is a phase-one clinical trial designed to test the treatment's safety and feasibility, all patients enrolled in the trial will receive the cardiac stem cell therapy.

Individuals wishing to learn more about this study should call 502-852-1387 or email cardiactrial@louisville.edu.

Video of a news briefing along with b-roll with the physicians and the patient will be uplinked today, July 24, via satellite from 12-1 p.m. (EDT) at the following coordinates:

C-band AMC 6 Transponder 21

Uplink Frequency 6345 Horizontal

Downlink Frequency 4120 Vertical


'/>"/>
SOURCE Jewish Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
3. Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
4. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
5. CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment
6. Northern California Cancer Centers First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival
7. First Potential Lupus-Specific Treatment in Sight
8. GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
9. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
10. McCaughey Urges Use of First NYS Hospital Infection Report
11. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):